For the SEND Public Meeting in April, FDA posed three questions to the CDISC SEND Team. At that time, the responses shared in the public meeting on 27-April-2022 were generated from a subset of SEND team members and considered preliminary. Since that time, the same questions were posed to the broader nonclinical community (via CDISC Website and links shared in email and social media). The complete set of responses is included in the presentation below. In the presentation below, the responses are verbatim, by bullet point, and aggregated by type of organization. The responses should not be interpreted as the views of any specific organization.